Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121 – OncLive
|
Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121
OncLive Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma. In a study of 21 patients, bb2121 was … |
